Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

By LabMedica International staff writers
Posted on 17 Nov 2026

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. More...

Assessing brain amyloid pathology can guide clinical decisions, but diagnostic pathways may be complex. A newly available blood test aims to simplify this assessment in symptomatic adults aged 40 and older.

C2N Diagnostics’ FDA-cleared PrecivityAD2 blood test is now available for ordering by health care professionals. The first FDA-cleared Alzheimer’s disease test for adults with cognitive symptoms as young as 40, it is designed to support clinical evaluation and guide next steps, including consideration of disease-modifying treatment options.

PrecivityAD2 uses high-resolution mass spectrometry to measure two blood biomarkers: the percentage of phosphorylated tau 217 (%p-tau217) and the amyloid-beta 42/40 (Aβ42/40) ratio. A proprietary algorithm combines these measurements into the Amyloid Probability Score 2 (APS2), which indicates the likelihood of brain amyloid pathology, a hallmark of Alzheimer’s disease.

The test was clinically validated across different age groups, sexes, and disease stages, demonstrating consistent performance across common comorbidities, including metabolic, cardiovascular, autoimmune, oncologic, mental health, and renal conditions. It is intended to help health care professionals experienced in evaluating cognitive impairment assess the likelihood of brain amyloid pathology in primary and specialized care settings.

C2N’s diagnostic technologies have been used in more than 200 Alzheimer’s disease and related research studies in the United States and internationally. More than 90,000 Precivity-related biomarker measurements have been reported in peer-reviewed publications, with additional research manuscripts currently under review.

“We’ve been waiting for this moment since the FDA initially informed us that its review had cleared the PrecivityAD2 test. The availability of the PrecivityAD2 test across the country through health care professionals means patients and families will have a clearer picture of brain amyloid plaque, a hallmark sign of Alzheimer’s disease. Overall, this will help streamline and simplify the complex diagnostic pathway that many patients face when dealing with serious memory concerns,” said Dr. Joel Braunstein, C2N Co-Founder, CEO and President.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
POC Immunoassay Analyzer
Procise DX
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.